|
|
Дата |
---|
18:25 |
31.07.2025 |
29.07.2025 |
28.07.2025 |
25.07.2025 |
21.07.2025 |
16.07.2025 |
15.07.2025 |
09.07.2025 |
07.07.2025 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
0.1301
|
0.1775
|
0.1775
|
0.1306
|
0.1775
|
0.1538
|
|
|
488.32
|
6.00
|
0.10
|
0.288
|
0.1337
|
0.1337
|
0.15
|
0.15
|
|
|
219.54
|
7.00
|
0.10
|
0.288
|
0.13
|
0.13
|
0.18
|
0.18
|
|
|
1 027.49
|
12.00
|
0.10
|
0.255
|
0.222
|
0.19
|
0.222
|
0.19
|
|
|
476.84
|
12.00
|
0.222
|
0.288
|
0.1061
|
0.1061
|
0.277
|
0.1999
|
|
|
3 607.34
|
85.00
|
0.0971
|
0.288
|
0.097
|
0.097
|
0.0971
|
0.0971
|
|
|
34.54
|
2.00
|
0.097
|
0.288
|
0.0971
|
0.097064
|
0.10
|
0.0999
|
|
|
186.42
|
6.00
|
0.097
|
0.288
|
0.0971
|
0.0971
|
0.0971
|
0.0971
|
|
|
16.84
|
4.00
|
0.0865
|
0.288
|
0.1095
|
0.1095
|
0.1096
|
0.1096
|
|
|
287.74
|
6.00
|
0.0836
|
0.288
|
0.0902
|
0.0902
|
0.0902
|
0.0902
|
|
|
13.50
|
2.00
|
Biofrontera Inc. (Biofrontera) is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions. With a focus on the fields of photodynamic therapy (PDT) and topical antibiotics, Biofrontera currently commercializes the FDA-approved flagship drug Ameluz (aminolevulinic acid hydrochloride gel, 10%) in the United States. When used in combination with PDT and Biofrontera’s BF-RhodoLED lamp, Ameluz-PDT is indicated for the treatment of actinic keratoses (AK), one of the most common precancerous skin conditions. Biofrontera also commercializes the drug Xepi (ozenoxacin cream, 1%), FDA-approved for the treatment of impetigo.
In collaboration with dermatologists, Biofrontera is fully committed to advancing treatment options and patient care.
Показать все Скрыть